reason report
robust franchis outlook reduc covid
result beat consensu revenu ep provid revis
financi guidanc lighter expect top
bottom line downward revis revenu guidanc
attribut effect covid pandem slower new patient
start increas discontinu neg product
compani report revenu vs
con vs us non-gaap ep vs con
us rel strong top-lin result estim
consensu non-gaap ep beat estim
consensu base lower expens higher margin
estim consensu
alexion report impress ultomiri sale
yoy vs us vs consensu partial
off-set less impress perform soliri
guidanc full-year reflect expect impact
lower revenu non-gaap ep guidanc
initi guidanc
lower recent estim
consensu estim new
oper margin guidanc
primarili reflect reduc oper expens guidanc relat
clinic trial delay pipelin updat well
reduct sg due reduc commerci activ expens
guidanc decreas previous
consensu estim sg guidanc
reduc
consensu estim updat guidanc
includ potenti impact acquisit would expect
actual oper expens higher reflect acquisit
andexxa-rel cost deal close
soliri sale beat consensu estim
total sale soliri grow qoq
yoy driven continu growth gener myasthenia
gravi gmg revenu partial off-set ultomiri convers dynam
alexion reiter neurolog busi remain largest
franchis driven sequenti volum growth reiter
expect expans treat us neurolog patient
popul
ultomiri easili beat expect acceler transit
soliri alexion report ultomiri sale
higher estim consensu accord
pleas refer page import disclosur price chart analyst certif
compani paroxysm nocturn hemoglobinuria pnh convers
percentag increas versu versu end decemb
result suggest ultomiri uptak acceler
like result conveni dose
schedul overal alexion continu expect ultomiri reach
convers rate
metabol yoy rel flat sequenti basi
strensiq sale estim
consensu yoy volum growth kanuma sale
consensu estim
suspect out-performance strensiq driven smaller
impact rel kanuma due abil at-hom administr
ep beat driven stronger expect top-lin lower
expect oper expens total product revenu
beat consensu estim
respect top-lin beat primarili driven stronger
expect perform franchis non-gaap expens
consensu estim
non-gaap sg expens
estim consensu non-gaap
consensu
estim alexion paid tax rate
averag dilut share count million quarter
non-gaap basi report non-gaap ep
consensu estim
impact reflect updat guidanc
earn call manag provid updat guidanc
suggest moder top-lin oper expens expect
compani guid total product sale versu
prior earn call guidanc repres
rel declin midpoint substanti lower
recent consensu estim
due three primari factor includ volum impact anticip
slower patient start price headwind due acceler ultomiri
convers shift public payer due rise unemploy
also appear impair treatment persist
particularli hard-hit intern market spain itali
reduct complianc would expect rel larger
impact result compar new start compani indic
continu see strong complianc us expect
complianc treatment-delay relat impact like
preferenti impact indic gmg oppos
pnh sinc patient less like becom symptomat treatment
interv extend compani increas oper margin
guidanc repres increas
midpoint rel initi guidanc
driven expens reduct due clinic trial delay remov
affibodi mileston reduct like off-set
increas clinic trial spend expand access program
invest virtual promot activ ep compani
guid pro forma ep midpoint
initi guidanc lower recent consensu
estim compani indic
anticip suppli disrupt due
includ impact acquisit updat guidanc
guidanc particularli expens pro forma ep
like advers affect recent announc acquisit
close year
timelin key pipelin program larg intact slight
delay due portfolio adjust manag
provid updat across compani pipelin extens
alexion commentari acquisit call yesterday alexion
highlight critic care franchis potenti area growth
particularli given nearli atyp hemolyt urem syndrom
ahu grown number neuromyel optica spectrum disord
nmosd patient initi therapi hospit set
seem eager develop scope product offer
acquisit plan pursu potenti indic
andexxa includ urgent surgeri set alexion also
initi random phase trial ultomiri sever
pneumonia ard assess overal surviv
day recent acquir achillion portfolio alexion plan begin
phase studi assess danicopan pnh patient extravascular
hemolysi guid toward top-lin readout
phase studi quarter compani indic
new clinic trial like experi delay due
obviou timelin chang relat plan launch
studi al-amyloidosi trial
expect start previous phase studi
danicopan pnh push back
previous timelin fcrn program also push back due
combin decis transit iv sq formul
waiha well delay phase sq studi
healthi volunt result alexion plan initi phase trial
waiha previous expect gmg previous
expect addit alexion indic plan
pursu dose schedul bispecif mini-bodi
via auto-injector pre-fil syring decid discontinu
develop clinic develop program ultomiri ppm
base retrospect clinic biomark analysi
sale non-gaap
share count period dilut
guidanc
